404
Participants
Start Date
October 31, 2013
Primary Completion Date
November 30, 2014
Study Completion Date
November 30, 2014
liraglutide
Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
lixisenatide
Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
Novo Nordisk Investigational Site, Budapest
Novo Nordisk Investigational Site, Budapest
Novo Nordisk Investigational Site, Budapest
Novo Nordisk Investigational Site, Salgótarján
Novo Nordisk Investigational Site, Gyula
Novo Nordisk Investigational Site, Baja
Novo Nordisk Investigational Site, Pécs
Novo Nordisk Investigational Site, Berlin
Novo Nordisk Investigational Site, La Rochelle
Novo Nordisk Investigational Site, Pilsen
Novo Nordisk Investigational Site, Cittadella (PD)
Novo Nordisk Investigational Site, Padua
Novo Nordisk Investigational Site, Bad Lauterberg im Harz
Novo Nordisk Investigational Site, Jyväskylä
Novo Nordisk Investigational Site, Hinx
Novo Nordisk Investigational Site, Saint-Herblain
Novo Nordisk Investigational Site, Bochum
Novo Nordisk Investigational Site, Duisburg
Novo Nordisk Investigational Site, Kaunas
Novo Nordisk Investigational Site, Hradec Králové
Novo Nordisk Investigational Site, Kaunas
Novo Nordisk Investigational Site, Friedrichsthal
Novo Nordisk Investigational Site, Saint Ingbert
Novo Nordisk Investigational Site, Strasbourg
Novo Nordisk Investigational Site, Ludwigshafen
Novo Nordisk Investigational Site, Lampertheim
Novo Nordisk Investigational Site, Vénissieux
Novo Nordisk Investigational Site, Šiauliai
Novo Nordisk Investigational Site, Olomouc
Novo Nordisk Investigational Site, Prostějov
Novo Nordisk Investigational Site, Palermo
Novo Nordisk Investigational Site, Corbeil-Essonnes
Novo Nordisk Investigational Site, Boulogne-Billancourt
Novo Nordisk Investigational Site, Klaipėda
Novo Nordisk Investigational Site, Catania
Novo Nordisk Investigational Site, Rovaniemi
Novo Nordisk Investigational Site, Mladá Boleslav
Novo Nordisk Investigational Site, Helsinki
Novo Nordisk Investigational Site, Oulu
Novo Nordisk Investigational Site, Pori
Novo Nordisk Investigational Site, Dresden
Novo Nordisk Investigational Site, Szeged
Novo Nordisk Investigational Site, Terni
Novo Nordisk Investigational Site, Ogre
Novo Nordisk Investigational Site, Riga
Novo Nordisk Investigational Site, Riga
Novo Nordisk Investigational Site, Riga
Novo Nordisk Investigational Site, Riga
Novo Nordisk Investigational Site, Vilnius
Novo Nordisk Investigational Site, Basingstoke
Novo Nordisk Investigational Site, Bristol
Novo Nordisk Investigational Site, Chester
Novo Nordisk Investigational Site, Chiswick
Novo Nordisk Investigational Site, Coventry
Novo Nordisk Investigational Site, Derby
Novo Nordisk Investigational Site, Devon
Novo Nordisk Investigational Site, Great Yarmouth
Novo Nordisk Investigational Site, Lancaster
Novo Nordisk Investigational Site, Plymouth
Novo Nordisk Investigational Site, Sandbach
Novo Nordisk Investigational Site, Taunton
Lead Sponsor
Novo Nordisk A/S
INDUSTRY